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Abstract 
Reactive oxygen species (ROS) are crucial in long-term diabetes complications, including peripheral 
artery disease (PAD). In this study, we have investigated the potential clinical impact of unacylated 
ghrelin (UnAG) in a glucose intolerance and PAD mouse model. We demonstrate that UnAG is able 
to protect skeletal muscle and endothelial cells (ECs) from ROS imbalance in hind limb ischemia–
subjected ob/ob mice. This effect translates into reductions in hind limb functional impairment. 
We show that UnAG rescues sirtuin 1 (SIRT1) activity and superoxide dismutase-2 (SOD-2) 
expression in ECs. This leads to SIRT1-mediated p53 and histone 3 lysate 56 deacetylation and 
results in reduced EC senescence in vivo. We demonstrate, using small interfering RNA technology, 
that SIRT1 is also crucial for SOD-2 expression. UnAG also renews micro-RNA (miR)-126 expression, 
resulting in the posttranscriptional regulation of vascular cell adhesion molecule 1 expression and 
a reduced number of infiltrating inflammatory cells in vivo. Loss-of-function experiments that 
target miR-126 demonstrate that miR-126 also controls SIRT1 and SOD-2 expression, thus 
confirming its role in driving UnAG-mediated EC protection against ROS imbalance. These results 
indicate that UnAG protects vessels from ROS imbalance in ob/ob mice by rescuing miR-126 
expression, thus emphasizing its potential clinical impact in avoiding limb loss in PAD. 
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Introduction 
Peripheral arterial disease (PAD) is a widespread condition caused by the atherosclerosis of 
peripheral arteries, most commonly in the lower extremities (1). Patients with both type 1 and 
type 2 diabetes display an increased risk of developing PAD (2,3). Moreover, individuals with 
diabetes develop PAD at an early age, and greater PAD severity is commonly caused by impaired 
vascular remodeling (2,3). The persistence of an oxidative environment is crucial for symptom 
occurrence/recurrence in the diabetic setting (3). A defective mitochondrial electron transport 
chain (4), along with an increase in reactive oxygen species (ROS) levels, are crucial determinants 
of tissue damage in PAD patients. This is particularly true in diabetes, in which endogenous 
antioxidant defense mechanisms are also impaired (3,5). 
The role of glucose-mediated oxidative stress in vascular damage has been extensively 
documented and is considered to be the most relevant mechanism in what is known as metabolic 
memory (6–8). Metabolic memory refers to the long-term detrimental effects of hyperglycemia, 
maintained even after glucose normalization. It mainly relies on changes in the epigenome (6–8) 
and involves histone-modifying enzymes, DNA methylation, chromatin remodeling proteins, and 
micro-RNAs (miRs) (6–8). Proof of concept for the role of impaired ROS clearance in 
hyperglycemia-induced changes in the epigenome (9) can be found in the molecular approach-
driven overexpression of superoxide dismutase-2 (SOD-2), the primary enzymatic antioxidant 
defense against ROS production, which prevents the sugar-induced histone methylation of the NF-
κB subunit p65 (9). The transcriptional activation of NF-κB and the expression of its target genes, 
such as the vascular cell adhesion molecule 1 (VCAM-1), are some of the most relevant markers of 
epigenome modification in diabetes (9). In addition to the role of transcription factor NF-κB, 
posttranscriptional regulation, involving small noncoding miRs, is known to control VCAM-1 
expression and inflammatory cell recruitment in developing atherosclerotic lesions and 
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subsequent ischemia (10). Interestingly, the plasma miR profile of diabetic patients has revealed 
that miR-126, one of miRs involved in the regulation of VCAM-1 expression (11), is reduced (12). 
This suggests that aberrant miR-126 regulation might also contribute to the long-lasting 
detrimental vascular effects of hyperglycemia. Persistent downregulation of class III histone 
deacetylase sirtuin 1 (SIRT1) (13), in individuals suffering from diabetes has also recently been 
reported to contribute to mitochondrial superoxide accumulation, reduced scavenging enzyme 
activity, NF-κB activation, p53 and histone 3 lysate 56 (H3K56) acetylation, as well as vascular 
dysfunction (8,13,14). 
Surgical and endovascular treatment are currently considered to be the front line in avoiding limb 
loss (15). However, restenosis is commonly found in up to 50% of patients with successful 
angioplasty (16). Moreover, alternative treatment options are still limited for PAD patients who 
are not eligible for surgery. Therapeutic angiogenesis has recently been proposed for these 
patients, but has failed to improve long-term patient outcomes (2). The failure to obtain a clinical 
response to current therapeutic options has spurred the development of alternative strategies, 
which are mainly focused on improving antioxidant machinery. We have previously shown that the 
more abundant circulating form of ghrelin, unacylated grelin (UnAG), exerts antioxidant effects on 
endothelial progenitor cells (EPCs) (17,18). A proof of concept is provided by UnAG administration, 
which induces SOD-2 expression and improves mitochondrial dysfunction in muscles subjected to 
ischemia (19). UnAG is one of the ghrelin forms that is mainly produced in the stomach (20). UnAG 
differs from acylated ghrelin (AG) in term of its biological activity (17–19,21). Moreover, while 
both AG and UnAG are released into circulation (22), their ratio (AG/UnAG) varies and ranges from 
1:2 to 1:9 (23), while a relative excess of AG has interestingly been found in individuals suffering 
from insulin resistance–connoted metabolic disorders (24). These observations, coupled with the 
role of glucose-mediated oxidative stress in vascular damage, have led us to investigate the clinical 
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impact of UnAG administration on a mouse model of massive obesity, glucose intolerance, and 
PAD. 
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Research Design and Methods 
Reagents 
A detailed list of the reagents and antibodies used in this study is reported in Supplementary Table 
1. 
Murine Hind Limb Ischemia Model 
Male C57BL/6J ob/ob mice (8 weeks old) (Charles River Laboratories International Inc., 
Wilmington, MA) were anesthetized on day 0, and unilateral hind limb ischemia was induced as 
described in Hellingman et al. (25). The normoperfused contralateral limb of each mouse was 
used as an internal control. After hind limb ischemia, animals were treated daily with 
intraperitoneal injection from day 0 to day 21 using either saline or UnAG (pharmacological dose: 
100 μg/kg) (19,26,27). Mice were treated according to European guidelines and policies as 
approved by the University of Turin Ethical Committee. 
Laser Doppler Perfusion Imaging 
Mice were anesthetized as above and subjected to a noninvasive assessment of ischemic limb 
microvascular perfusion using the laser Doppler perfusion imaging system (PIM3; Perimed) 
(performed at WIL Research Europe, Saint Germain-Nuelles, France). Details are reported in the 
Supplementary Data. 
In Vivo Assessment of Limb Function 
A semiquantitative estimation of foot damage (two-way ANOVA followed by the post hoc test 
using the Bonferroni correction for multiple comparison) was performed serially using the 
following classification: 3, dragging of foot (foot necrosis); 2, no dragging but no plantar flexion 
(foot damage); 1, plantar flexion but no toe flexion (toe damage); and 0, flexing the toes to resist 
gentle traction on the tail (no damage) (28). 
Histological, Immunofluorescence, and Immunohistochemistry Analysis 
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Gastrocnemius muscles were recovered from the ischemic and normoperfused limbs of treated 
animals, fixed in 10% formalin, and embedded in paraffin. Tissue sections were stained with 
hematoxylin and eosin for histological analysis. The proportion of fibers with central nuclei 
(regenerating fibers) in the injured area was counted as previously described (19). Muscle 
sections were processed for immunofluorescence assays and immunohistochemistry analyses as 
previously described (29). A quantification of cells that expressed the indicated markers was 
obtained as previously described (30). Images were acquired using a Zeiss LSM 5 Pascal confocal 
laser-scanning microscope (Carl Zeiss, Jena, Germany) (19). Details are reported in the 
Supplementary Data. 
Cell Cultures and In Vitro Ischemia 
For the ex vivo experiments, endothelial cells (ECs) were isolated (31) from gastrocnemius 
muscles that had been subjected to ischemia. Details are reported in the Supplementary Data. For 
the in vitro experiments, primary ECs were either cultured for 2 days in 10% (volume for volume) 
bovine calf serum and basic fibroblast growth factor alone or in combination with 400 μg/mL 
advanced glycosylation end product (AGE) or 25 mmol/L d-glucose and either treated with UnAG 
(1 µmol/L) or not. At day 3, in vitro ischemia was induced as previously described (19). Satellite 
cells (SCs) were also isolated as described in Musarò and Barberi (32). 
Senescence 
Senescence was performed as previously described (33). Details are reported in the 
Supplementary Data. 
Western Blot Analysis and Nuclear Extracts 
Cells were lysed and processed as previously described (34). H3K56 acetylation was evaluated on 
nuclear extracts from ECs. Details are reported in the Supplementary Data. 
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p53 Acetylation 
Cells were lysed in a cold DIM buffer supplemented with 10 μmol/L trichostatin A. Equal amounts 
of protein (500 μg) were immunoprecipitated using the p53 monoclonal antibody (see 
Supplementary Data). Bound proteins were eluted and processed as previously described (35). 
Immunoprecipitates were subjected to SDS-PAGE and blotted with the antiacetylated Lys382 p53 
antibody. 
RNA Isolation and Quantitative Real-Time PCR for miRs 
Total RNA was isolated using the TRIzol reagent (Invitrogen) from ECs recovered from the muscles 
of treated animals or from ECs subjected to in vitro ischemia. Samples were processed as 
previously described (31). Loss-of-function experiments were performed in ECs transfected with 
an anti-miR negative control or an anti–miR-126 antagonist according to the manufacturer’s 
instructions. 
Statistical Analysis 
All data are presented as mean ± SEMs. The D'Agostino-Pearson test was used to test normality. 
Data on blood perfusion, damage score, number of vessels, percentage of regenerating fibers, 
inflammatory cells, and miR-126 and VCAM-1 expression from the ischemic and nonischemic limbs 
of treated ob/ob mice at days 7 and 21 were analyzed using two-way ANOVA, followed by the post 
hoc test with the Bonferroni correction for multiple comparisons. Data on blood glucose, body 
weight, HbA1c measurements from adhesion assays, senescence assays, ROS generation, nitric 
oxide (NO) production, CD31/SOD-2 colocalization, CD31/SIRT1 colocalization, proliferating cell 
nuclear antigen (PCNA) expression, on glucose and insulin tolerance test assays, from luciferase 
assays, on miR-126 expression in in vitro or loss-of-function experiments, and SIRT1 and SOD-2 
inactivation were analyzed using one-way ANOVA followed by Tukey multicomparison post hoc 
test. Densitometric analysis data for the Western blots were analyzed using Student t tests for 
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two-group comparison and one-way ANOVA, followed by Tukey's multiple comparison test, for ≥3 
groups. The cutoff for statistical significance was set up at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 
0.001). All statistical analyses were carried out using GraphPad Prism version 5.04 (Graph Pad 
Software). 
Blood glucose measurements, cell proliferation, FACS analyses, adhesion assays, SIRT1 and SOD-2 
silencing, oxidative stress, NO detection, glucose and insulin tolerance tests, and the luciferase 
gene reporter are reported in the Supplementary Data. 
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Results 
UnAG Protects ob/ob Muscles Against Hind Limb Ischemia 
PAD is one of the most challenging medical-surgical diseases worldwide (1–3). The beneficial 
vascular effects of UnAG (17,19) have led us to investigate UnAG's therapeutic potential in ob/ob 
mice with PAD. ob/ob Mice that had been subjected to unilateral hind limb ischemia were treated 
daily (starting at day 0) with either saline or UnAG. No significant differences in large vessel 
reperfusion (Fig. 1A) were detected in the treatment groups as shown by laser Doppler perfusion 
imaging performed at the indicated number of days postsurgery. However, the functional scores 
reported in Fig. 1B demonstrate a significantly higher damage score in the saline- than in the 
UnAG-treated group. UnAG-treated ob/ob mice contained an increased number of regenerating 
myofibers in ischemia-subjected muscles (Fig. 1C and D), which is consistent with data obtained in 
wild-type mice (19). Also consistent with our previous data (19) is the finding that UnAG was able 
to induce an expansion in SCs (Pax-7+/MyoD+ cells) as well as their terminal differentiation 
(myogenin+ cells) (Fig. 1E). In order to investigate the possibility that such differences depended 
on UnAG-mediated vascular protection, the number of vessels in ischemic and nonischemic 
muscles was counted in the two groups of mice. As shown in Fig. 2A, saline-treated mice showed 
significantly lower capillary density in this study than in the contralateral muscles, unlike UnAG-
treated animals. The expression of PCNA and cyclin D1 was then evaluated in ECs recovered from 
the ischemic muscles of saline and UnAG mice so as to rule out the possibility that proliferation 
signals may be able to mediate UnAG effects. We found that both PCNA and cyclin D1 expression 
were similar in the two animal groups at days 7 and 21 after surgery (PCNA: saline, day 7 = 24.09 ± 
5.2; UnAG, day 7 = 20.3 ± 3.3; saline, day 21 = 20.73 ± 4.6; UnAG, day 21 = 24.5 ± 3.8; n = 3) (Fig. 
2B). No changes in plasma glucose concentration (saline, 326.3 ± 28.9; UnAG, 310.1 ± 31.2 mg/dL), 
body weight (saline, 45.83 ± 0.76; UnAG, 45.91 ± 0.9 g), HbA1c (saline, 12.38 ± 1.09%; UnAG, 11.89 
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± 1.19), or insulin sensitivity (Supplementary Fig. 1A and B) were detected in UnAG mice over the 
entire treatment period. Thus, it can be said that UnAG protects vessels against ischemia-induced 
damage in ob/ob mice independently of metabolic control. In Vivo UnAG Protects Vessels Against 
ROS Production by Inducing SOD-2 
Impaired antioxidant machinery and increased ROS production are crucial mediators of vascular 
damage in diabetes (36). This is particularly true in PAD patients (37), and so ECs recovered from 
ischemic muscles were first evaluated for intracellular ROS content. Data reported in Fig. 2C 
demonstrate a significant decrease in ROS generation in UnAG over saline-treated mice. In order 
to validate the possibility that UnAG promotes its biological effects by inducing an efficient 
antioxidant response, the mitochondria-specific antioxidant enzyme SOD-2 was evaluated in 
vessels. We demonstrate that the intramuscle vessels of UnAG-treated mice express high levels of 
SOD-2 (Fig. 2D). Similar results were obtained in ex vivo experiments (Fig. 2E). 
UnAG Increases the Levels of SIRT1 in Ischemic Vessels and Protects ECs From Senescence 
It has been reported that the impaired SIRT1 level contributes to superoxide mitochondrial 
accumulation in both diabetes- and insulin resistance–connoted metabolic disorders (38–40). We 
therefore evaluated SIRT1 expression in both saline and UnAG animals. Data reported in Fig. 3A 
demonstrate that UnAG treatment was associated with increased SIRT1 expression in vessels. ECs 
were recovered from ischemic muscles and analyzed for SIRT1 expression as a means to validate 
these observations. As expected, ex vivo experiments demonstrated that ECs that had been 
recovered from UnAG animals displayed increased SIRT1 content (Fig. 3B) both in ischemic and 
nonischemic muscles. Moreover, a reduced level of H3K56 acetylation (Fig. 3C) (14) and a reduced 
number of senescent ECs were found in ob/ob mice challenged with UnAG (Fig. 3D), which is 
consistent with the role of SIRT1 in regulating EC fate. SIRT1 Is Required for UnAG-Mediated EC 
Stress Resistance Upon Ischemia 
12 
 
ECs were treated with AGE and subjected to in vitro ischemia to further deepen the understanding 
of these data. Fig. 4A–C demonstrates that a UnAG challenge interferes with ROS generation and 
was able to induce both SOD-2 and SIRT1 expression. Moreover, in a finding that is consistent with 
our previous data in EPCs (17), we demonstrate that UnAG was able to increase NO levels in an 
ischemic setting (Supplementary Fig. 1C). Similar results were obtained using high glucose 
concentrations (data not shown). AGE was thus used throughout the study. We found that 
pS36p66Shc (38) was reduced in these experimental conditions, as expected from SIRT1 
expression (Fig. 4D). In addition, p53 acetylation was also reduced upon UnAG treatment, and, in 
accordance with ex vivo experiments, this effect was associated with a reduced number of 
senescent ECs (Fig. 4E and F). These data were further confirmed by silencing SIRT1 
(Supplementary Fig. 2A and Fig. 5A–D). Finally, UnAG treatment is only effective in reducing H3K56 
acetylation in cells that express SIRT1, in vitro as well (Figs. 4G and 5E). Moreover, UnAG-induced 
SIRT1 activity is not enhanced by the activation of AMP-activated protein kinase (AMPK) (41), 
unlike calorie restriction (Fig. 4H). 
It has been shown that SIRT1 activates, via its deacetylation ability, peroxisome proliferator 
activated receptor-γ coactivator 1α, which is involved in SOD-2 expression (42). ECs were 
therefore silenced for SIRT1 and subjected to the same experimental conditions. SIRT1 silencing 
led to reduced SOD-2 expression and increased ROS generation, even in the presence of UnAG, as 
shown in Fig. 5F and G. These data indicate that SIRT1 is crucial for UnAG-mediated SOD-2 
expression and p53 and H3K56 deacetylation. 
UnAG Hampers EC Activation and Prevents Inflammatory Cell Recruitment in Ischemic Conditions 
Oxidative stress–mediated EC activation strictly controls inflammatory cell recruitment in ischemic 
conditions (2,3). We found that the ischemic muscles of UnAG mice had a reduced number of 
CD68-positive inflammatory cells (Fig. 6A). In order to investigate the possibility that UnAG 
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treatment protects ECs against oxidative stress–induced activation, the expression level of VCAM-
1 was evaluated. Indeed, we found that vessels from UnAG animals express low levels of VCAM-1 
at days 7 and 21 after ischemia when compared with control animals (Fig. 6B). Similar results were 
obtained both ex vivo (Fig. 6C) and in vitro when diabetes and ischemia were recapitulated (Fig. 
6D and Supplementary Fig. 2B). It has been reported that molecular approaches that force SOD-2 
expression led to reduced VCAM-1 expression (9,10). Thus, ECs that had been silenced for SOD-2 
were evaluated (Supplementary Fig. 2C). As expected, high levels of VCAM-1 and an increased 
number of mononuclear cells that were adherent to ECs were detected, even in presence of UnAG 
(Fig. 6E and Supplementary Fig. 2D). Similar results were obtained when ECs were silenced for 
SIRT1 (Fig. 5H). 
Posttranscriptional Mechanisms Involving miR-126 Are Crucial for UnAG Protection Against 
Ischemia 
Besides precise transcriptional regulation, posttranscriptional regulation involving miR-126 is 
known to play a role in VCAM-1 expression (11). Indeed, reduced miR-126 plasma levels have been 
observed in diabetic patients' miR profile (12). Therefore, miR-126 levels were evaluated first on 
ECs recovered from ischemic muscles of UnAG- and saline-treated mice. The results shown in Fig. 
7A demonstrate that the miR-126 level decreased even in ECs from saline animals. By contrast, the 
miR-126 level was high in ECs recovered from UnAG mice. Again, the effects of UnAG were 
evaluated in vitro. In accordance with the ex vivo experiments, a UnAG challenge led to miR-126 
upregulation in ECs treated with AGE and subjected to ischemia (Fig. 7B, left panel). In order to 
gain further insight into the possibility that the posttranscriptional mechanism controls VCAM-1 
expression upon UnAG treatment, the direct effect of miR-126 on VCAM-1–3′-untranslated region 
(UTR) was evaluated by transfecting ECs with the luciferase reporter vector containing wild-type 
full-length VCAM-1–3′-UTR. Increased luciferase activity was only detected in VCAM-1–3′-UTR that 
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expressed ECs that had been exposed to AGE and in vitro ischemia, but not when the same 
experiments were performed in the presence of UnAG (Fig. 7C). Furthermore, UnAG no longer had 
any effect on ROS production, VCAM-1 expression, or the adhesion of mononuclear cells to ECs 
(Fig. 7D and Supplementary Fig. 3) in loss-of-function experiments involving the transfection of ECs 
with anti–miR-126 antago-miRs (Fig. 7B, right panel). Interestingly, we also noticed that SOD-2 and 
SIRT1 content, as well as p53 and H3K56 deacetylation, were reduced by the knocking down of 
miR-126 (Fig. 7E–G). Furthermore, UnAG was no longer effective in protecting ECs from ROS 
production. 
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Discussion 
In this study, we have shown that UnAG improves hind limb functional score in a mouse model of 
insulin resistance and PAD by protecting vessels against ROS-mediated damage. In particular, we 
have noticed that UnAG rescues ROS imbalance by restoring miR-126 expression, as well as SIRT1 
and SOD-2 levels in vessels from ischemic muscles. These results indicate that restoring the 
AG/UnAG ratio in an insulin resistance setting can offer clinical benefits in the treatment of PAD 
and provide novel mechanistic insight into UnAG action. 
The imbalance of two different forces, ROS and antioxidants, is crucial in long-term diabetic 
complications, including PAD (3,5,37). Indeed, the persistence of an oxidative milieu and the 
inefficient antioxidant machinery in diabetic patients with PAD also contribute to mitochondrial 
damage, leading to the activation of a vicious circle that clinically results in the appearance of 
symptoms (3,5,37). In the current study, we demonstrate that UnAG administration to mice with 
insulin resistance and PAD induces skeletal muscle regeneration. A resident population of adult 
stem cells, named SCs, is present in skeletal muscles and contributes to muscle regeneration after 
ischemia (43). In accordance with our previous data (19), we found that UnAG promotes SC 
expansion in response to ischemia. This effect results in a low damage score that, however, 
appears to be independent of neovascularization (PCNA and cyclin D1 content in ECs recovered 
from both saline and UnAG mice was similar), but arguably dependent on its antioxidant effects on 
ECs. As proof of concept in UnAG mice, the number of vessels in ischemic muscles was comparable 
to the number in nonischemic ones, and ECs recovered from ischemic muscles exhibited low levels 
of intracellular ROS. This suggests that UnAG, besides inducing muscle regeneration, exerts its 
beneficial effects in our PAD model of insulin resistance by improving the antioxidant machinery in 
ECs as well. 
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Physiologically, superoxide radicals from mitochondria are dismutated to hydrogen peroxide and 
oxygen by a class of enzymes called superoxide dismutases (37). Such a first line of defense against 
ROS mainly depends on SOD-2 (37). Human and rodent studies provide evidence for impaired 
SOD-2 expression in PAD muscles, particularly in patients with diabetes (37). We demonstrate in 
this study that SOD-2 expression is also reduced in the vessels of saline-treated mice, while it was 
highly expressed in vessels from UnAG-treated animals, in vivo and ex vivo. That UnAG can induce 
EC resistance against oxidative stress via SOD-2 is further sustained by data obtained in SOD-2–
silenced ECs. 
It has been reported that glucose-mediated oxidative stress and NAD+ depletion is associated with 
the impaired expression of SIRT1 in diabetic patient peripheral cells (40). We found that, in ob/ob 
mice, the SIRT1 level was lower in ECs recovered from both ischemic and nonischemic muscles of 
saline mice, while it increased upon a UnAG challenge. A number of SIRT1 targets have been 
described in mammals (44), and tumor suppressor p53 is included (38). Transcription factor p53 is 
involved in DNA damage mechanisms (45). However, it also acts as a negative regulator of cell 
proliferation in human atherosclerotic lesions (46) and contributes to accelerated vascular cell 
senescence in diabetes (47). We have previously reported that the silencing of p53 in EPCs from 
diabetic patients prevents cell senescence (47). We demonstrate in this study that UnAG-induced 
SIRT1 expression results in p53 deacetylation and EC protection against senescence in the ischemic 
condition. The pS36p66Shc level further sustains this (48). 
The occurrence of vascular complications in diabetes has recently been linked to the complex 
interactions between genes and environmental cues that are driven by the persistence of high 
glucose concentrations (6–8). The impaired clearance of ROS of mitochondria origin is the most 
relevant environmental cue in the long-lasting detrimental effect of hyperglycemia (6–8). Growing 
amounts of evidence indicate that mechanisms that account for so-called “metabolic memory” 
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rely on the epigenetic regulation of gene expression, which can be irreversible over time (6–8). 
The important role that epigenetics play in long-term diabetes-associated vascular complications 
means that particular attention has been devoted to developing therapeutic strategies that erase 
epigenetics. We demonstrate in this study that, in diabetic mice subjected to ischemia, UnAG has 
no effect on blood glucose metabolism but interferes with some epigenetic, hyperglycemia-
associated mechanisms, including histone modifying enzymes and miRs. In fact, UnAG increases 
SIRT1 expression by restoring miR-126 expression in ECs, which is, in turn, involved in p53 and 
H3K56 deacetylation and protection against DNA damage (8,13,14). Moreover, SIRT1 rescue 
translates into SOD-2 expression, which restores an efficient antioxidant response and further 
protects vessels against ROS-mediated damage. Overall, UnAG treatment recapitulates the 
beneficial vascular effects of SOD-2 overexpression (6,9,10). Finally, UnAG also prevents EC 
activation and inflammatory cell recruitment into ischemic tissues via miR-126–driven VCAM-1 
posttranscriptional regulation. It has been extensively documented that the oxidant-sensitive 
expression of adhesion molecules is a crucial determinant of lesion progression during 
atherosclerosis evolution (3,5). In addition, ROS imbalance is believed to play a major role in 
accelerating vascular dysfunction and PAD in diabetes. Thus, UnAG might also protect vessels that 
are prone to atherosclerosis from undergoing lesion progression by rescuing miR-126 expression 
and interfering with mechanisms that control inflammatory cell homing. Finally, as NO 
bioavailability loss in ECs is a crucial feature of endothelial dysfunction, the increased endothelial 
NO detected in ECs treated with UnAG, besides controlling vascular tone, could further prevent 
atherogenesis and PAD progression. 
We have previously shown that UnAG improves diabetic EPC mobilization by rescuing endothelial 
NO synthase activity in bone marrow (17). We have not analyzed EPC's contribution in the 
ischemic model; however, the impaired inflammatory cell recruitment observed in UnAG animals 
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strongly suggests that UnAG protection, rather than relying on EPC homing, may rely on their 
functional improvement. In accordance with this possibility is the fact that renewing miR-126 
levels in diabetes rescues EPC functional capabilities and protects them against apoptosis (49). 
Overall, these data provide further evidence to support the theory that restoring the AG/UnAG 
ratio in insulin resistance–connoted pathological settings can have an impact on patients' 
cardiovascular risk factor profile. 
The incidence of PAD, in particular, in diabetic patients is high and considered the most 
challenging of medical-surgical diseases (16). As current therapeutic approaches have failed to 
improve long-term outcomes, new therapeutic options for PAD are urgently needed. Even though 
an optimal treatment has yet to be identified, our results indicate that UnAG administration to 
ob/ob animals counteracts oxidative stress-mediated vascular dysfunction and offers clinical 
benefits in the treatment of PAD (Fig. 8). Although we have no direct evidence to suggest that 
restoring UnAG plasma concentrations in the insulin resistance state can ameliorate overall clinical 
outcomes, data provided in this study suggest that UnAG or UnAG-related peptides may constitute 
an alternative therapeutic approach to the management of one of the most relevant vascular 
complications in insulin resistance–connoted pathological settings. Finally, the results of this 
study, together with the role of mitochondrial dysfunction in the development of several 
metabolic and age-related disorders, suggest that exploiting UnAG-related peptides or UnAG 
receptor-specific agonists may also be a useful therapeutic strategy with which to address a 
number of currently unmet medical needs that require ROS scavenging. 
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Figure Legends 
Figure 1 
UnAG protects ob/ob mice against ischemia-induced functional impairment. A: Histogram 
representation of blood perfusion reported as ratio (mean ± SEM, n = 13 for each group) of 
ischemic to normal hind limb for both groups of mice (0b, before surgery; 0a, after surgery). B: 
Foot damage score was evaluated for the indicated times. Data are expressed as mean ± SEM; n = 
13. *P < 0.05 UnAG vs. saline in ischemic limb. C: Representative hematoxylin and eosin–stained 
sections of ischemic muscles from saline- and UnAG-treated mice, at days 7 and 21 postsurgery. 
Scale bars, 80 μm (×20 magnification). Insets show regenerating myofibers at higher 
magnification. D: Quantification of the percentage (mean ± SEM) of regenerating fibers, 
characterized by the presence of a centrally located nucleus. UnAG- and saline-treated mice were 
analyzed at days 7 and 21 postsurgery. *P < 0.05 UnAG-treated mice at day 7 vs. day 21; ***P < 
0.001 ischemic muscles of UnAG- vs. saline-treated mice at days 7 and 21. E: Cell extracts from 
SCs recovered from ischemic muscles at days 7 and 21 were analyzed by Western blot for Pax-7, 
MyoD, and myogenin content and normalized to tubulin content. **P < 0.01 myogenin from 
UnAG-treated mice at day 7 vs. day 21; ***P < 0.001 Pax-7 and MyoD content in ischemic SCs 
from UnAG- vs. saline-treated mice at day 7; ***P < 0.001 myogenin content in ischemic SCs from 
UnAG- vs. saline-treated mice at day 21; ***P < 0.001 Pax-7 and MyoD from UnAG-treated mice 
at day 7 vs. day 21. A–D: n = 13 each group at days 7 and 21. E: n = 3 each group at days 7 and 21. 
LDPI, laser Doppler perfusion imaging 
Figure 2 
UnAG protects the intramuscle vessels of ob/ob mice subjected to hind limb ischemia and 
increases SOD-2 expression. A: Sections of ischemic muscles recovered from saline- and UnAG-
treated mice at days 7 and 21 postsurgery were stained for CD31 (red) and DAPI (blue). Red 
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arrows indicate vessels. Scale bars, 40 μm (×40 magnification). The graph on the right represents 
the number of vessels in ischemic (ih) and normoperfused (nh) gastrocnemius muscles as 
evaluated by three different operators counting 10 fields at ×40 magnification and reported as 
mean ± SEM (n = 7 each group at days 7 and 21) of vessels per field. ***P < 0.001 ih muscles of 
UnAG mice vs. ih muscles of saline mice at days 7 and 21. B: Cell extracts of ECs recovered from 
ischemic muscles of treated mice at days 7 and 21 were analyzed for cyclin D1 content by 
Western blot and normalized to β-actin content. The results are representative of three different 
experiments. C: Intracellular ROS generation was analyzed using a Amplex Red fluorescence assay 
kit on ECs recovered from muscles of treated mice by cell-magnetic sorting at day 21 after 
ischemia. The fluorescence level (mean ± SEM, n = 3 each group) is reported as fold induction 
relative to “saline” values, which were arbitrarily set as 100. *P < 0.05 UnAG- vs. saline-treated 
mice. D: Representative stained sections for CD31 (red), SOD-2 (green), and DAPI (blue) of 
muscles recovered at days 7 and 21 postsurgery. Insets show SOD-2 and CD31 colocalization at 
higher magnification. Scale bars, 40 μm (×40 magnification). Quantification of SOD-2+/CD31+ cells 
per field (×40 magnification) in ischemic vessels of treated mice is reported in the graph at right 
(mean ± SEM, n = 7 each group). ***P < 0.001 UnAG- vs. saline-treated mice at days 7 and 21. E: 
Cell extracts of ECs recovered from ischemic muscles of treated mice at day 21 were analyzed for 
SOD-2 content by Western blot and normalized to β-actin content. The results are representative 
of three different experiments. *P < 0.05 ECs from UnAG- vs. saline-treated mice. 
Figure 3 
UnAG increases SIRT1 levels in ischemic vessels and protects ECs from senescence. A: 
Representative stained sections for CD31 (red), SIRT1 (green), and DAPI (blue) of muscles 
recovered at days 7 and 21 after ischemia. Insets show SIRT1 and CD31 colocalization at higher 
magnification. Scale bar, 40 μm (×40 magnification). Quantification of SIRT1+/CD31+ cells per field 
28 
 
(×40 magnification) in ischemic vessels of treated mice is reported in the graph (mean ± SEM, n = 
7 each group) (***P < 0.001 UnAG- vs. saline-treated mice at days 7 and 21). B: ECs recovered 
from nonischemic or ischemic muscles as described in research design and methods were 
subjected to Western blot analysis for SIRT1 content. Protein levels were normalized to β-actin 
content. **P < 0.01 UnAG- vs. saline-treated mice for nonischemic ECs (top); **P < 0.01 UnAG- vs. 
saline-treated mice for ischemic ECs (bottom); n = 3. C: Cell extracts from ECs recovered from the 
ischemic muscles of treated mice were analyzed for H3K56ac content, which was normalized to 
H3 content. **P < 0.01 UnAG vs. saline; n = 3. D: Senescence was evaluated on ECs recovered 
from ischemic muscles at day 21 and expressed as the mean ± SEM of SA–β-gal–positive cells per 
field. **P < 0.01 UnAG vs. saline; n = 3. H3K56ac, H3K56 acetylation. 
Figure 4 
In vivo UnAG effects are recapitulated in ECs subjected to in vitro ischemia. A: Intracellular ROS 
generation was evaluated using an Amplex Red fluorescence assay kit in ECs subjected to in vitro 
ischemia and untreated (c) or treated with AGE (A), UnAG (U), or AGE+UnAG (A+U). Fluorescence 
level (mean ± SEM, n = 4) is reported as fold induction relative to control values, which were 
arbitrarily set as 100. **P < 0.01 AGE-treated vs. untreated ECs; ***P < 0.001 UnAG-treated and 
AGE+UnAG vs. AGE-treated ECs. Cell extracts from ECs subjected to in vitro ischemia and treated 
as indicated were analyzed for SIRT1 (B), SOD-2 (C), and pS36p66Shc (p-p66Shc) (D) content, 
normalized to β-actin and p66Shc content, or for acetylated and total p53 content (E). *P < 0.05 
for p-p66Shc UnAG and AGE+UnAG vs. untreated or AGE-treated ECs; **P < 0.01 for SIRT1, ***P < 
0.001 for SOD-2 (C), ***P < 0.001 for acetylated p53 in UnAG and AGE+UnAG vs. AGE (E). F: 
Senescence was evaluated on ECs treated as above and expressed as the mean ± SEM of SA–β-
gal–positive cells per field. ***P < 0.001 UnAG and AGE+UnAG vs. untreated or AGE. Empty bar, 
control (ctrl); diagonal line bar, AGE; horizontal line bar, UnAG; and black bar, UnAG+AGE. Nuclear 
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H3K56ac (G) and cytoplasmatic phospho-(p)-AMPK (H) content was evaluated in ECs treated as 
indicated. Protein levels were normalized to H3 or AMPK content, respectively. ***P < 0.001 AGE 
vs. untreated and UnAG or AGE+UnAG vs. AGE for H3K56ac. All results are representative of four 
different experiments performed in triplicate. H3K56ac, H3K56 acetylation; IB, immunoblot; IP, 
immunoprecipitation. 
Figure 5 
SIRT1 is required for UnAG-mediated stress resistance upon ischemia. A–C: ECs that were 
untreated (c) or treated with AGE (A), UnAG (U), or AGE+UnAG (A+U) were transfected for 48 h 
with SIRT1 small interfering RNA (siRNA) and subjected to in vitro ischemia. Western blot analysis 
was performed to evaluate the content of SIRT1 (A) and pS36p66Shc (p-p66Shc) (B), normalized 
to β-actin and p66Shc content and acetylated or total p53 content (C). D: Senescence was 
evaluated on ECs treated as above and expressed as the mean ± SEM of SA–β-gal–positive cells 
per field. Empty bar, control (ctrl); diagonal line bar, AGE; horizontal line bar, UnAG; and black 
bar, UnAG+AGE. Cell extracts from ECs treated as above were subjected to Western blot analysis 
to evaluate H3K56ac and H3 content (E) or SOD-2, VCAM-1, and β-actin content (F). G: 
Intracellular ROS generation was evaluated using the Amplex Red fluorescence assay kit in ECs 
treated as indicated and subjected to in vitro ischemia. Fluorescence level (mean ± SEM, n = 4) is 
reported as fold induction relative to control values, which were arbitrarily set as 100. H: The 
adhesion assay was performed by plating red-labeled peripheral blood mononuclear cells on an 
EC monolayer that had previously been silenced for SIRT1. Treatments are indicated. Adherent 
cells were counted and reported as mean ± SEM per field (×20 magnification). All results are 
representative of four different experiments performed in triplicate. H3K56ac, H3K56 acetylation; 
IB, immunoblot; IP, immunoprecipitation. 
 
30 
 
Figure 6 
UnAG hampers EC activation and prevents inflammatory cell recruitment in ischemic conditions. 
A: Sections of ischemic muscle that had been recovered from saline- and UnAG-treated mice, 7 
and 21 days postsurgery, and stained for CD68 (red) and DAPI (blue). Scale bars, 40 μm (×40 
magnification). Quantification of inflammatory cells in the ischemic muscles from treated mice at 
indicated times is reported. Data are expressed as mean ± SEM (n = 7 each group at day 7 and day 
21) of CD68+ cells per field (×40 magnification). ***P < 0.001 ischemic muscles of saline- vs. 
UnAG-treated mice at days 7 and 21. B: Representative sections of VCAM-1 expression in the ECs 
of muscles recovered at days 7 and 21 postsurgery from saline- and UnAG-treated mice. 
Immunohistochemistry analyses are reported. Scale bars, 40 μm (×40 magnification). 
Quantification of VCAM-1+ cells per field (×40 magnification) in ischemic vessels of treated mice is 
reported in the graph (mean ± SEM, n = 7 each group). ***P < 0.001 UnAG- vs. saline-treated mice 
at days 7 and 21. C: ECs recovered from ischemic muscles at day 21 were subjected to Western 
blot analysis for VCAM-1 content. Protein levels were normalized to β-actin content. *P < 0.05 
UnAG- vs. saline-treated mice; n = 3. D: Cell extracts from ECs subjected to in vitro ischemia and 
treated as indicated were evaluated for VCAM-1 and β-actin content. *P < 0.05 AGE+UnAG vs. 
AGE; ***P < 0.001 AGE vs. untreated cells. E: ECs untreated (c) or treated with AGE (A), UnAG (U), 
or AGE+UnAG (A+U) were transfected for 48 h with small interfering RNA (siRNA) of SOD-2 and 
subjected to in vitro ischemia. Western blot analysis was performed to evaluate the content of 
SOD-2 and VCAM-1, normalized to β-actin content. The results in D and E are representative of 
four different experiments performed in triplicate. 
Figure 7 
miR-126 is crucial for UnAG-mediated vessel protection against ischemia. A: miR-126 expression 
was evaluated by quantitative real-time PCR on ECs recovered from the ischemic muscles of mice 
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treated as indicated at days 7 and 21 postsurgery. Data normalized to RNU6B are representative 
of three experiments (n = 3 each group). ***P < 0.001 UnAG- vs. saline-treated mice at days 7 and 
21. B: miR-126 expression was evaluated by quantitative real-time PCR in two groups of ECs that 
had either undergone transfection with anti–miR-126 oligonucleotides or not were treated with 
the indicated stimuli and subjected to in vitro ischemia. Data normalized to RNU6B are 
representative of four experiments. **P < 0.01 AGE+UnAG vs. AGE (left); **P < 0.01 treated vs. 
untreated ECs transfected with anti–miR-126 (right); ***P < 0.001 UnAG vs. untreated cells. C: 
ECs were either transfected with pGL3 empty vector or pGL3–3′-UTR full-length–VCAM-1 
luciferase constructs, treated as indicated, and subjected to in vitro ischemia. Relative luciferase 
activity is reported. ***P < 0.001 AGE vs. untreated cells and AGE+UnAG vs. AGE; n = 4. Empty 
bar, control (c); diagonal line bar, AGE (A); horizontal line bar, UnAG (U); and black bar, 
UnAG+AGE (A+U). Cell extracts from ECs transfected with anti–miR-126 and treated as above 
were analyzed for VCAM-1 (D), SIRT1 and SOD-2 (E), and H3K56ac (F) content, normalized to β-
actin or H3 content, as indicated, or for acetylated and total p53 content (G). The results in D–G 
are representative of four different experiments performed in triplicate. ctrl, control; H3K56ac, 
H3K56 acetylation; IB, immunoblot; IP, immunoprecipitation. 
Figure 8 
Schematic representation of UnAG effects following ischemia. Following muscle damage, UnAG 
induces skeletal muscle regeneration via SC proliferation and differentiation and vascular cell 
protection. Its effects are mediated by miR-126 upregulation. The increased level of miR-126 
leads to: a) increased SIRT1 expression, which prevents cell senescence via epigenetic 
mechanisms (reduced p53 and H3K56 acetylation); b) increased SOD-2 expression, which protects 
ECs from ROS generation and, in turn, contributes to avoiding cell senescence; and c) reduced 
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VCAM-1 expression and inflammatory cell recruitment. H3K56ac, H3K56 acetylation; p53ac, 
acetylated p53. 
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